<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554085</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-2158-201</org_study_id>
    <nct_id>NCT01554085</nct_id>
  </id_info>
  <brief_title>First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002158 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alios Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alios Biopharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, 3-part study will assess the safety,&#xD;
      tolerability, and pharmacokinetics of orally administered ALS-002158 in healthy volunteers&#xD;
      (HV) and subjects with chronic hepatitis C (CHC) genotype 1 infection.&#xD;
&#xD;
      Part 1 will assess single ascending dosing pharmacokinetics and safety in HV. Part 2 will&#xD;
      assess food effects on pharmacokinetics in HV.&#xD;
&#xD;
      Part 3 will assess multiple ascending dosing pharmacokinetics and safety in subjects with CHC&#xD;
      genotype 1 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical&#xD;
    development.&#xD;
  </why_stopped>
  <start_date type="Actual">December 31, 2011</start_date>
  <completion_date type="Actual">September 30, 2012</completion_date>
  <primary_completion_date type="Actual">September 30, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tabulation of adverse events, physical exam, vital signs, 12-lead ECGs, and clinical lab results</measure>
    <time_frame>Part 1: Day 1-8; Part 2: Day 1-16; Part 3: Day 1-31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters and urinary excretion of ALS-002158 and metabolites</measure>
    <time_frame>Part 1: Day 1-8; Part 2: Day 1-16; Part 3: Day 1-31</time_frame>
    <description>Maximum measured drug concentration (Cmax), time of maximum concentration (tmax), half-life (t1/2), apparent oral clearance (CL/F), area under the concentration time curve from time zero to infinity (AUC0-inf) or area under the concentration time curve from time zero to last quantifiable concentration (AUC0-last), area under the concentration time curve during the dosing interval (AUC0-tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV ribonucleic acid (RNA) viral load reduction</measure>
    <time_frame>Baseline to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequence analysis of the Hepatitis C virus (HCV) NS5B region</measure>
    <time_frame>Baseline up to Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>ALS-002158</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALS-002158</intervention_name>
    <description>ALS-002158</description>
    <arm_group_label>ALS-002158</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided written consent.&#xD;
&#xD;
          -  Subject is in good health as deemed by the investigator&#xD;
&#xD;
          -  Creatinine clearance of greater than 50 mL/min (Cockcroft- Gault).&#xD;
&#xD;
          -  Male or female, 18-55 years of age for HV and 18-65 years of age for subjects with&#xD;
             CHC.&#xD;
&#xD;
          -  Body mass index (BMI) 18-32 kg/m2 inclusive for HV and 18-36 kg/m2 for subjects with&#xD;
             CHC, minimum weight 50 kg in both populations.&#xD;
&#xD;
          -  A female is eligible to participate in this study if she is of non-childbearing&#xD;
             potential.&#xD;
&#xD;
          -  If male, subject is surgically sterile or practicing specific forms of birth control.&#xD;
&#xD;
        Additional inclusion criteria for subjects with CHC genotype 1 infection:&#xD;
&#xD;
          -  Positive HCV antibody and a positive HCV RNA at screening.&#xD;
&#xD;
          -  Documentation of CHC infection of greater than 6 months duration at screening.&#xD;
&#xD;
          -  CHC genotype 1 infection at screening.&#xD;
&#xD;
          -  HCV RNA viral load ≥ 105 and ≤ 108 IU/mL using a sensitive quantitative assay&#xD;
&#xD;
          -  Liver biopsy within two years or Fibroscan evaluation within 6 months prior to&#xD;
             screening that clearly excludes cirrhosis. Fibroscan liver stiffness score must be &lt;&#xD;
             12 kPa.&#xD;
&#xD;
          -  Absence of hepatocellular carcinoma as indicated by an abdominal ultrasound scan&#xD;
             during screening.&#xD;
&#xD;
          -  No prior treatment for CHC.&#xD;
&#xD;
          -  Absence of history of clinical hepatic decompensation.&#xD;
&#xD;
          -  Laboratory values include:&#xD;
&#xD;
               -  prothrombin time &lt; 1.5 × ULN.&#xD;
&#xD;
               -  platelets &gt; 120,000/mm3.&#xD;
&#xD;
               -  albumin &gt; 3.5 g/dL, bilirubin &lt; 1.5 mg/dL at screening (subjects with documented&#xD;
                  Gilbert's disease allowed).&#xD;
&#xD;
               -  Serum ALT concentration &lt; 5 × ULN.&#xD;
&#xD;
               -  Alpha Fetoprotein (AFP) concentration ≤ ULN. If AFP is ≥ ULN, absence of a&#xD;
                  hepatic mass must be demonstrated by ultrasound within the screening period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant cardiovascular, respiratory, renal, gastrointestinal,&#xD;
             hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric&#xD;
             disorder.&#xD;
&#xD;
          -  Positive test for HAV IgM, HBsAg, HCV Ab (HV only), or HIV Ab.&#xD;
&#xD;
          -  Abnormal screening laboratory results that are considered clinically significant by&#xD;
             the investigator.&#xD;
&#xD;
          -  Clinically significant drug allergy such as, but not limited to, sulfonamides and&#xD;
             penicillins, including those experienced in previous trials with experimental drugs.&#xD;
&#xD;
          -  Participation in an investigational drug trial or having received an investigational&#xD;
             vaccine within 30 days or 5 half lives (whichever is longer) prior to receiving study&#xD;
             medication.&#xD;
&#xD;
          -  Clinically significant blood loss or elective blood donation of significant volume.&#xD;
&#xD;
          -  Laboratory abnormalities including:&#xD;
&#xD;
               -  Thyroid Stimulating Hormone (TSH) &gt;ULN.&#xD;
&#xD;
               -  Hematocrit &lt; 34 %.&#xD;
&#xD;
               -  White blood cell counts &lt; 3,500/mm3.&#xD;
&#xD;
          -  For healthy volunteers, history of regular use of tobacco.&#xD;
&#xD;
          -  The subject has a positive pre-study drug screen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>QPharm</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Services</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust Ltd.</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

